Blood Purification Medical Devices Revolutionizing the Future of Health from Cancer to COVID

Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary highlights advancements in blood purification medical devices, focusing on Aethlon Medical's (NASDAQ: AEMD) Hemopurifier®. The global blood purification market is projected to grow from USD 17.8 billion in 2021 to USD 29.2 billion by 2030. Aethlon plans Phase 1 trials in Australia and India for patients with stable or progressive solid tumors not responding to anti-PD-1 therapies. The Hemopurifier® aims to remove cancer-promoting exosomes and viruses. The FDA has designated it a 'Breakthrough Device' for specific cancers and viral infections. Data from recent in vitro studies support its efficacy in removing extracellular vesicles from cancer patient plasma, facilitating further clinical trials.

  • Global blood purification market projected to grow from USD 17.8 billion in 2021 to USD 29.2 billion by 2030.
  • Hemopurifier® designated as a 'Breakthrough Device' by the FDA for specific cancers and viral infections.
  • Planned Phase 1 trials in Australia and India for patients with solid tumors not responding to anti-PD-1 therapies.
  • Recent in vitro data shows Hemopurifier® effective in removing extracellular vesicles from cancer patient plasma.
  • Positive in vitro data integrated into Ethics Committee documentation for clinical trial approvals.
  • Clinical trials are still in the early stages, with Phase 1 trials planned but not yet initiated.
  • Dependency on Ethics Committee approvals which could delay trial commencement.
  • Potential for delayed commercialization if clinical trial outcomes are not favorable.
  • Significant competition in the blood purification market from companies like CytoSorbents, Cerus , and Spectral Medical.

The update from Aethlon Medical, Inc. regarding the development of its Hemopurifier® device for oncology patients highlights significant progress in the medical device field, especially for those who are unresponsive to anti-PD-1 monotherapy. The planned phase 1 clinical trials in Australia and India mark a pivotal step towards potential commercialization and regulatory approval. These trials will scrutinize the safety, feasibility and appropriate dosing of the Hemopurifier®.

This device is particularly important due to its unique mechanism of removing cancer-promoting exosomes from blood, which can impede the progression of solid tumors. The FDA's designation of the Hemopurifier® as a 'Breakthrough Device' underscores its potential impact. However, investors should remain mindful of the regulatory hurdles and the timelines associated with clinical trials. An ongoing challenge will be to demonstrate efficacy in clinical settings similar to the in vitro results.

In the short term, positive outcomes from the trials could lead to an increase in stock value due to heightened investor confidence. Long-term implications include potential market capture and sustained revenue growth if the device proves effective and gains widespread adoption. However, the competitive landscape in blood purification, with companies like CytoSorbents and Cerus making strides, suggests that Aethlon must continue to innovate and provide clear clinical benefits to stand out.

The global blood purification equipment market is projected to grow significantly, from $17,755.6 million in 2021 to $29,242.21 million by 2030. This growth trajectory indicates a robust demand for innovative solutions like Aethlon's Hemopurifier®. The company's strategic focus on both oncology and infectious diseases broadens its market potential, considering the increasing prevalence of such conditions.

From an investor's perspective, Aethlon's ongoing clinical trials and the FDA's 'Breakthrough Device' designation can be considered strong indicators of future commercial success. However, it is important to monitor the competitive environment, which includes players like CytoSorbents and Cerus, who are also making notable advancements. CytoSorbents reported a 14% year-over-year increase in product sales, illustrating strong demand in this sector.

Aethlon’s collaboration with international clinical sites, particularly in regions like Australia and India, can be seen as a strategic move to diversify and potentially expedite the approval process. This international focus could mitigate some regulatory risks associated with the U.S. market alone.

From a financial standpoint, Aethlon Medical’s focus on expanding its Hemopurifier® trials into international markets like Australia and India represents a strategic effort to enhance their market valuation and investor confidence. The FDA's 'Breakthrough Device' designation is a significant milestone, potentially accelerating the regulatory approval process, which could translate into earlier revenue generation.

Investors should note that the current financial health of the company will be important as it moves forward with these trials. Costs associated with clinical trials can be substantial and the success of these trials will heavily impact the company’s ability to secure additional funding or partnerships. The comparison with other industry players like CytoSorbents, which reported a 14% increase in product sales and expanded gross margins, provides a benchmark for financial performance expectations.

In the short term, positive trial outcomes and subsequent approvals could result in significant stock appreciation. However, it is essential to consider the financial risk associated with trial failures or delays, which could negatively impact stock performance and financial stability.

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 3, 2024) -, a go-to investing platform, releases the first of a two-part series looking at medical device advancements for blood purification, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

Read the full article on

According to Straits Research, "The global blood purification equipment market size was valued at USD 17,755.6 million in 2021. It is expected to reach USD 29242.21 million by 2030."

Aethlon Medical, Inc. (NASDAQ: AEMD), with a long history of development for its patented Hemopurifier® blood purification device, just released an update on its planned phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.

"We continue to make progress preparing for our planned, safety, feasibility and "dose finding" oncology trials in Australia and India, and want to provide our shareholders and other constituents with an update," stated Steven LaRosa, MD, Chief Medical Officer of Aethlon Medical. "In early May, we announced new data showing the in vitro removal of exosomes from cancer patient plasma using a miniature version of our Hemopurifier®. This data has been quickly integrated into the required documentation for Ethics Committees at our potential clinical sites. On May 17, 2024, we provided these documents to the Contract Research Organizations for these planned clinical trials. Subsequently, on May 24, 2024, one potential site submitted the documents to its Ethics Board. An additional site in Australia and another in India are currently assembling the packages for submission to their Ethics Committees."

"Once we receive the expected Ethics Committee approvals, we will finalize the Clinical Trial Agreements. After this, hospitals can begin recruiting patients for the trials."

As a reminder, the target patient population for these safety, feasibility, and dose finding trials is oncology patients with solid tumors who are failing their anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.

The Aethlon Hemopurifier® is a first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and circulating viruses. The United States Food and Drug Administration (FDA) has designated the Hemopurifier® as a "Breakthrough Device" for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and life-threatening viruses that are not addressed with approved therapies.

Zach's Research recently commented on Aethlon following positive data from an in vitro binding study it had implemented of the potential for the Hemopurifier® to remove extracellular vesicles (EVs) directly from plasma of cancer patients.

"The data from this in vitro study is a critical element enabling the company to move the Hemopurifier forward in clinical oncology studies towards potential regulatory approval and commercialization. The company next intends to add this data to its Clinical Investigator Brochure, which will then be submitted to the Ethics Committees at clinical sites that are interested in participating in the planned phase 1 oncology trials in Australia and India. We expect AEMD to submit the Clinical Investigator Brochure this month."

"AEMD will then seek to obtain approval by the respective Ethics Boards of interested sites in India. The company has a strong clinical working relationship with Medanta Medicity Hospital in Delhi, India, which is currently participating in a study of the Hemopurifier in COVID patients and it would not surprise us if Medanta Medicity Hospital had interest in participating in the oncology study."

"Depending on how long it takes for the sites to review and potentially approve moving forward to participate in Aethlon's phase 1 trial, we believe clinical efforts could begin in 2H24. If Aethlon can demonstrate the ability of the Hemopurifier to improve outcomes of cancer patients suffering from a variety of different cancer types, we would anticipate strong commercial prospects for the Hemopurifier."

In early May, CytoSorbents Corporation, a pioneer in critical care and cardiac surgery blood purification technologies, announced unaudited financial and operating results for the quarter ended March 31, 2024. The Company reported a robust 14% increase in product sales year over year and a sequential quarterly increase of 22%.

From the news: Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, "We are pleased to announce a strong start to 2024, driven by significant sales growth and operational efficiencies. First quarter 2024 product sales were $9.0 million, marking the highest quarter for core CytoSorb sales in nearly 3 years. We expanded our product gross margins to 76%, exclusive of a non-recurring inventory adjustment, up an absolute 8% from Q1 2023, which we believe highlights the scalability and efficiency of our state-of-the-art manufacturing facility and processes."

Furthermore, Principal Investigator Dr. Michael Mack presented the results of the U.S. and Canada pivotal STAR-T (Safe and Timely Antithrombotic Removal of Ticagrelor) randomized controlled trial at the Annual Meeting of the American Association for Thoracic Surgery (AATS) and at the KOL and Investor/Analyst Day we hosted earlier this week (replay available) that we believe support a favorable benefit-to-risk profile of the DrugSorb-ATR system* in the perioperative bleeding risk of patients undergoing isolated coronary artery bypass graft (CABG) surgery within 2 days of receiving Brilinta® (ticagrelor, AstraZeneca). We received positive and encouraging feedback on the importance of these data and the continued unmet medical need from cardiothoracic surgeons. Looking ahead, we expect to submit marketing applications for DrugSorb-ATR, which has an FDA Breakthrough Device Designation, to the FDA under the De Novo pathway, and Health Canada in the third quarter of 2024."

Also focused on blood purification, Cerus Corporation, dedicated solely to safeguarding the world's blood supply, announced financial results for the first quarter ended March 31, 2024.

Highlights included:

  • U.S. ReCePI Phase 3 clinical trial successfully met primary endpoint for INTERCEPT Blood System for Red Blood Cells in cardiovascular surgery patients.
  • Received FDA approval of extended shelf life for INTERCEPT Platelet Processing Sets to 12 months, doubling the previous shelf life.
  • Advanced the LED illuminator program towards the Company's target commercial launch in the EU in 2025.

The Company is reiterating its full-year 2024 annual product revenue guidance range of $172 million to $175 million. Included in this range is full-year 2024 guidance for INTERCEPT Fibrinogen Complex, which is expected to be between $8 million to $10 million.

"The Cerus team delivered against our plans for Q1, paving the way for the balance of 2024, with great progress on clinical milestones and a strong return to growth for our commercial business. The positive topline readout from ReCePI, the U.S. Phase 3 clinical trial for INTERCEPT Red Blood Cells, is a significant milestone for the program and for our efforts to potentially bring this product to the market globally," stated William "Obi" Greenman, Cerus' President and Chief executive Officer. "Red blood cells are the most commonly transfused blood components worldwide, and we are committed to providing the full INTERCEPT portfolio for all transfused blood components to our customers around the globe."

The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System of Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding associated with fibrinogen deficiency, including massive hemorrhage.

In mid- May, Spectral Medical Inc., a Phase 3 company seeking US FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ ("PMX"), announced its financial results for the first quarter ended March 31, 2024, and provided a corporate update.

PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.

From the news:Spectral has continued its significant progress throughout the first quarter of 2024 both clinically and operationally and year-to-date enrolled 25 patients for a total of 106 patients out of the 150 total patient's target. The Company is focused on the final push to fully enroll and finish the Tigris trial and believes that the continued onboarding of new Tigris sites since the fourth quarter of 2023 could further accelerate enrollment and allow Spectral to rapidly reach the 150-patients target, bringing the Company closer to FDA submission and potential FDA approval. In parallel to its clinical trial, the Company continues to work closely with its commercialization partner, Baxter. In Q1 2024, Baxter exercised its right to maintain its exclusive distribution for PMX products in the U.S. and Canada and paid Spectral a non-dilutive milestone payment. Additionally, Spectral and Baxter mutually agreed to amend the initial term of their commercial partnership to ten years post-FDA approval of PMX. The Company believes this amendment provides a mutually beneficial runway for the parties to maximize PMX commercial economics, while providing motivation for continued support and allocation of resources to the PMX partnership.

Blood Purification technology made headlines during the pandemic when several companies including Baxter International Inc. received emergency use authorization (EUA) from the US FDA. Baxter's approval was for the company's Oxiris filter set to treat patients who have confirmed COVID-19 and have been admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure in need of blood purification therapy to reduce pro-inflammatory cytokine levels, including use in continuous renal replacement therapy (CRRT).

Separate from its current focus on cancer treatment, Aethlon (NASDAQ: AEMD) investigates the potential for the use of the Hemopurifier® in viral diseases under an open Investigational Device Exemption (IDE) and their FDA Breakthrough Designation for "…the treatment of life-threatening glycosylated viruses that are not addressed with an approved therapy."

Based on our studies to date, the Hemopurifier can potentially clear many viruses that are pathogenic in humans, including HCV, HIV, Sars-CoV-2, and Ebola."

For the companies in this sector, the drive for innovation is 'in their blood', and with the global threats of viruses and future pandemics on the rise, it's a sector worth watching.

Research biotech and medical device/ tech stocks at

About - Big Investing Ideas is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

Disclaimer/Disclosure: This news article featuring AEMD is a paid for news release on -Our site does not make recommendations for purchases or sale of stocks, services or products. This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: Learn more about publishing your news release and our other news services and prices on the newswire Global investors must adhere to regulations of each country. Please read privacy policy:

Follow us on X @investorideas
Follow us on Facebook
Follow us on YouTube


To view the source version of this press release, please visit


What is the latest update on Aethlon Medical's Hemopurifier®?

Aethlon Medical plans Phase 1 clinical trials in Australia and India for its Hemopurifier® to treat solid tumors not responding to anti-PD-1 therapies.

What is the market projection for blood purification devices?

The global blood purification equipment market is projected to grow from USD 17.8 billion in 2021 to USD 29.2 billion by 2030.

What designations has the Hemopurifier® received from regulatory bodies?

The FDA has designated the Hemopurifier® as a 'Breakthrough Device' for the treatment of certain cancers and viral infections.

What recent data supports the efficacy of the Hemopurifier®?

Recent in vitro data shows the Hemopurifier® can remove extracellular vesicles from cancer patient plasma, supporting further clinical trials.

What are the potential risks associated with Aethlon Medical's clinical trials?

Potential risks include delays in Ethics Committee approvals and unfavorable clinical trial outcomes, which could delay commercialization.

Aethlon Medical, Inc.


AEMD Rankings

AEMD Latest News

AEMD Stock Data

Analytical Laboratory Instrument Manufacturing
United States of America